{"entity":{"id":"nct06817525","kind":"trial","name":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Henan Cancer Hospital, now recruiting.","summary":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC is a phase 2, randomised interventional study registered as NCT06817525 by Henan Cancer Hospital, with a registry enrolment figure of 64 participants, started 2024-11-06 and due to reach its primary completion in 2026-05-31. Interventions recorded: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1); 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1). Conditions listed: Triple-negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06817525","url":"https://clinicaltrials.gov/study/NCT06817525"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06817525","phase":"2","setting":"Nab-P+Cb+PD1 Inhibitor Neoadjuvant Therapy for Early TNBC: a Single Center, Non Blinded, Randomized Phase II Clinical Trial","sponsor":"Henan Cancer Hospital","enrolled":64,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06817525/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}